Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
The past week was eventful for the Danish biotech stocks. Genmab and Curasight posted positive phase II results, while others announced partnerships and acquisitions. However, overall the Danish biotech stocks declined. Even the share prices of the companies with positive news didn’t change much.
Only 7 of the 20 listed, Danish biotech companies published news the past week. 6 of the 20 companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date. Saniona continues to be the best performing stock this year.
Company news the past week
Ascendis Pharma
No news the past week
No news the past week
Cessatech
Cessatech and Ventis Pharma announce US partnership for CT001 (Link)
No news the past week
Positive results in uPAR-PET/MR Phase II study in brain cancer (Link)
Evaxion Biotech
No news the past week
Expres2ion
Phase III topline results announced for the COVID-19 booster vaccine candidate (Link)
Fluoguide
No news the past week
Genmab
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) (Link)
Gubra
Gubra acquires research service provider MiniGut ApS (Link)
Gubra launches share buy-back programme to hedge incentive scheme obligations (Link)
Initiator Pharma
Initiator Pharma completes recruitment in Phase IIb trial with pudafensine (IP2015) (Link)
IO Biotech
No news the past week
Pila Pharma
No news the past week
Saniona
No news the past week
Scandion Oncology
No news the past week
SynAct Pharma
No news the past week
ViroGates
No news the past week
Zealand Pharma
Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency (Link)
Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism (Link)
Y-mAbs Therapeutics
No news the past week
2cureX
No news the past week
SELECTED CASES
SHARE PRICE DEVELOPMENTS
On average, the Danish biotech stocks delivered a negative share price performance last week of -1.7%. In the past week, Evaxion Biotech became the best performing stock with an 8% increase. Cessatech, Curasight, Evaxion Biotech, Genmab, and Gubra announced partnerships, acquisitions and study results. However, the news did not have a big effect on the companies’ share price. Saniona, on the other hand, became the worst performing Danish biotech stock for the second week in a row with a 10% decrease without any company specific news. This should be seen in light of the fact that the stock has already risen 150% this year. Other major performers year-to-date include Curasight A/S and Fluoguide A/S after soaring 120-134%.
Overall the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 4.9%.
Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment
Overview of share price developments the past week, year-to-date and last twelve months
